Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural Nivolumab in RCC and NSCLC with Pleural Effusion
NCT04749602Phase 2Completed
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC). Started Aug 2020; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04749602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749602.